Projekt

XATOA – Xarelto + Acetylsalicylic Acid: Treatment

Abgeschlossen · 2019 bis 2021

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2019
Ende
2021
Finanzierungsart
Industrie
Studiendesign
Observational Model: Cohort Time Perspective: Prospective
Webseite
Projektpartner
BAYER
Kurzbeschreibung/Zielsetzung

The study aims to collect real-world data on treatment
patterns and decision points for treatment in patients with
coronary artery disease (CAD) or symptomatic peripheral
artery disease (PAD) treated with rivaroxaban 2.5 mg[BID]
for the prevention of atherothrombotic events in adult
patients at high risk of ischaemic events and to describe
outcomes of an antithrombotic regime based on dual
pathway inhibition (vascular dose of rivaroxaban 2.5 mg
[BID] plus low-dose ASA [OD]) across the broad range of
patient risk profiles encountered in routine clinical practice.
The primary objective in this study is:
• to describe treatment patterns in CAD or PAD
patients treated with rivaroxaban 2.5 mg [BID] plus
ASA 75-100 mg [OD] in routine clinical practice